JB Capital LLC Has $4.83 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• JB Capital LLC increased its holdings in Thermo Fisher Scientific Inc. by 64.7% in Q2, owning 11,903 shares worth approximately $4.83 million.
• Wall Street analysts have set a consensus price target of $593.43 for Thermo Fisher, with 16 analysts recommending a Buy and 6 a Hold.
• Insider trading activity includes significant sales by executives, with over 30,000 shares sold in the last three months, reflecting a decrease in their ownership stakes.

JB Capital LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 64.7% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,903 shares of the medical research company's stock after purchasing an additional 4,676 shares during the quarter. JB Capital LLC's holdings in Thermo Fisher Scientific were worth $4,826,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. CBIZ Investment Advisory Services LLC grew its position in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after acquiring an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific in the first quarter valued at about $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the first quarter valued at about $31,000. DiNuzzo Private Wealth Inc. grew its position in Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock valued at $31,000 after acquiring an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 140.6% during the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company's stock worth $31,000 after purchasing an additional 45 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on TMO shares. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. JPMorgan Chase & Co. lifted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a research note on Thursday. Barclays lifted their price objective on Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an "overweight" rating in a research note on Thursday, October 2nd. Finally, UBS Group lifted their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $593.43.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 in the last three months. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $534.92 on Friday. The company has a fifty day simple moving average of $487.44 and a 200 day simple moving average of $448.31. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a market cap of $201.99 billion, a P/E ratio of 30.94, a PEG ratio of 2.91 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the firm posted $5.37 EPS. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.